Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial

March 12th 2020

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers

March 11th 2020

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

Dr. Hellmann on the Impact of Systemic Therapy on Surgery in Ovarian Cancer

March 10th 2020

Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.

Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

March 10th 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

Dr. Salani on the Progression of Upfront Ovarian Cancer Treatment

March 7th 2020

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

March 4th 2020

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

March 4th 2020

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Dr. Chern on Challenges Regarding Germline Testing in Ovarian Cancer

March 3rd 2020

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

Frontline Maintenance Niraparib Takes Step Toward EU Approval in Ovarian Cancer

February 27th 2020

The European Medicines Agency has validated a Type II Variation for niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who have responded to platinum-based chemotherapy, regardless of biomarker status.

If Only That Phase III Oncology Trial Had Been Designed Differently

February 19th 2020

The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.

Dr. Chern on Important Germline and Somatic Mutations in Ovarian Cancer

February 18th 2020

Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses important germline and somatic mutations to be aware of in ovarian cancer.

Biomarker Research in Ovarian Cancer

February 14th 2020

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Optimal Testing Methods in Ovarian Cancer

February 12th 2020

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

The Rationale to Combine Prexasertib With LY3300054 in Ovarian Cancer

February 11th 2020

Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer

February 11th 2020

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

February 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

February 10th 2020

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.